

Media Contact: Judy Gonzalez

jgonzalez@trytonmedical.com

919-226-1490

Global Bifurcation Leader Tryton Medical Announces Events at TCT 2014

Clinical trial outcomes translated into real world use

Durham, N.C. – September 10 – Tryton Medical, Inc., the leading developer of stents to treat bifurcation lesions today announced activities highlighting the latest data and experience with the Tryton Side Branch Stent at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT), taking place at the Walter E. Washington Convention Center Washington, DC. The company will exhibit in booth 1327.

On **Monday, September 15th** **James B. Hermiller Jr., MD and Maciej Lesiak, MD, PhD will chair a symposium regarding the Tryton Side Branch Stent.** The symposium will discuss the clinical and angiographic outcomes from the IDE trial, review the historic body of clinical evidence, review real-world Tryton Stent cases and provide perspectives on treating a broad spectrum of bifurcation anatomies. Antonio L. Bartorelli MD, Philippe Généreux MD, Aaron V. Kaplan MD, Jens Flens Lassen MD PhD FESC and D. Christopher Metzger MD are scheduled to present at the symposium. The symposium will take place from 7-8 a.m. EST in Room 143B.

Additionally, the Tryton Stent will be featured in the following sessions:

- **Bifurcation Stenting: Advanced Concepts on Monday September 15th:** Is There a Role for a Dedicated Bifurcation Stent Device? Landscape and Lessons from the Tryton Trial”, presented by Antonio L. Bartorelli MD
- **Left Main PCI Technique on Tuesday September 16th:** “Dedicated Stents for Left Main PCI: Tryton, Axxess, Stentys, and Others”, presented by Eulogio J. Garcia MD

More information about TCT 2014 can be found at <http://www.tctconference.com/>.

The Tryton Side Branch Stent is commercially available in multiple countries within Europe, Middle East & Africa, is investigational in the US, and is not available in Japan. Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions.

About the Tryton Side Branch Stent System

The Tryton Side Branch Stent System is built for bifurcation using proprietary Tri---ZONE[®] technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single---wire balloon--- expandable stent delivery

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is the leading developer of novel stent systems for the treatment of bifurcation lesions. For more information please visit www.trytonmedical.com and follow the company on Twitter at @TrytonMedical1.

#